Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
NovaBridge Biosciences (NovaBridge), formerly I-Mab, is a biopharmaceutical company. It develops transformational medicines for therapeutic areas of immuno-oncology for the treatment of cancer. Its pipeline product portfolio includes givastomig, a potential best-in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer gastroesophageal junction and esophageal adenocarcinoma cancer; uliledlimab targets metastatic non-small cell lung cancer and solid tumors; ragistomig for refactory and replaced cancers and solid tumors; and VIS-101 which treats retinal vascular diseases. The company utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. It operates in China, Hong Kong and the US. NovaBridge is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
Suite 400, 2440 Research Blvd, Rockville, Maryland, 20850
Website
www.novabridge.com
Telephone
1 240 7456330
No of Employees
30
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NBP (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-108.1%
(2024 vs 2023)
Market Cap*
$247.5M
Net Profit Margin (2022)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
NovaBridge Biosciences premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Givastomig: |
| Gastric Cancer |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Financing Agreements | In August, the company received investment from Everest Medicines Ltd. |
| 2025 | Contracts/Agreements | In July, the company entered into an agreement to acquire a 100% stake in Bridge Health Biotech Co., Ltd. |
| 2024 | Contracts/Agreements | In June, the company entered into a collaboration with Bristol Myers Squibb to evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab and ABL Bio to treat patients with advanced Claudin 18.2-positive gastric and esophageal cancers. |
Competitor Comparison
| Key Parameters | NovaBridge Biosciences | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Akeso Inc | JW Cayman Therapeutics Co Ltd | CStone Pharmaceuticals Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | China | China | China | China |
| City | Rockville | Lianyungang | Zhongshan | Shanghai | Suzhou |
| State/Province | Maryland | Jiangsu | Guangdong | Shanghai | Shanghai |
| No. of Employees | 30 | 14,000 | 3,761 | 314 | 136 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wei Fu | Chairman | Executive Board | 2025 | 43 |
| Emmett T. Cunningham, Jr, MD, PhD | Vice Chairman | Executive Board | 2026 | 65 |
| Srishti Gupta | Chief Executive Officer; Director | Executive Board | 2026 | - |
| Sean Wuxiong Cao, PhD | Director; Chief Business Development Officer | Executive Board | 2025 | 59 |
| Ming Lei | Chief Financial Officer | Senior Management | 2025 | 29 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer